NY-DILIGENT
10.8.2021 13:47:07 CEST | Business Wire | Press release
Diligent Corporation , the global leader in SaaS governance, risk and compliance (GRC), announced today the launch of the marketplace’s most comprehensive ESG software solution – Diligent ESG – on its governance, risk, and compliance (GRC) platform. Diligent ESG is powered in part by the newly announced acquisition of Accuvio and builds on the company’s recent acquisitions of Galvanize and Steele Compliance.
Diligent’s holistic, purpose-built ESG platform will empower organizations to address the seminal components of ESG that matter most to their stakeholders as they strive to meet current reporting requirements while also planning and preparing for the future. The solution will act as a nexus for ESG data from diverse sources to support goal setting, risk monitoring and stakeholder reporting, including to the board of directors, across diversity, climate, workforce safety, third-party risk, cyber, and more.
“Leaders today face an uphill battle in trying to establish impactful ESG programs and demonstrate progress: lack of clarity around where to start, manual processes with data in disparate systems, and a fragmented reporting landscape,” said Brian Stafford, CEO of Diligent. “Now, they can count on Diligent’s agile platform to track their risk, compliance, and ESG data in one place, establish ESG targets, and implement the governance structures to achieve those targets. With a comprehensive ESG solution at their fingertips, our clients will be able to respond with confidence to evolving regulations and investor preferences through a broader GRC practice.”
“It’s no secret that current business information systems are not designed with ESG reporting in mind,” said Matt DiGuiseppe, head of Diligent’s ESG Center of Excellence. “We are excited to offer a solution that can transform information scattered across even the most complex multinational organizations into a comprehensive, actionable ESG dataset, leverages mature capabilities battle-tested for over 30 years in the audit and compliance world.”
With Diligent ESG, public and private organizations – regardless of where they are in their program maturity – will have a sophisticated solution to help them build and enhance their ESG program, evaluate and track progress toward their goals, and integrate the data into their corporate strategy. Key features and functionality will include:
- Automated data collection through robotic process automation that connects to multiple internal platforms and monitors performance against ESG objectives in real time
- Collection, calculation, and reporting of greenhouse gas (GHG) emissions across the entire value chain (scopes, 1, 2, and 3) – all in a way that is completely auditable
- Customizable reports and real-time dashboards support clear, consistent communication with internal and external stakeholders, including regulators, focused on ESG performance
- Seamless connection of internal ESG data with third-party data, facilitating benchmarking relative to peers and the market
- Validation of how ESG programs are impacting public sentiment and assessing governance practices and executive compensation against a database of global peers, leveraging Diligent’s data and analytics
To learn more about the Diligent ESG solution, visit: https://diligent.com/solutions/esg
About Diligent Corporation
Diligent is the leading governance, risk and compliance (GRC) SaaS provider, serving more than one million users from over 25,000 organizations around the globe. Our modern GRC platform ensures boards, executives and other leaders have a holistic, integrated view of audit, risk, information security, ethics and compliance across the organization. Diligent brings technology, insights and confidence to leaders so they can build more effective, equitable and successful organizations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005588/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom